<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Rafael Holdings, Inc. — News on 6ix</title>
<link>https://6ix.com/company/rafael-holdings-inc</link>
<description>Latest news and press releases for Rafael Holdings, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/rafael-holdings-inc" rel="self" type="application/rss+xml" />
<item>
<title>Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-announces-patent-licensing-agreement-with-mit-for-small-molecules-to-improve-myelination-in-apoe4-positive-alzheimers-disease</guid>
<pubDate>Wed, 22 Apr 2026 11:00:00 GMT</pubDate>
<description>License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s DiseaseNEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology (“MIT”) covering U.S. Patent No.12285440. This license covers the use of cyclo</description>
</item>
<item>
<title>Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-second-quarter-fiscal-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-second-quarter-fiscal-2026-financial-results</guid>
<pubDate>Mon, 16 Mar 2026 20:01:00 GMT</pubDate>
<description>NEWARK, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31, 2026. “We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Tra</description>
</item>
<item>
<title>Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-first-quarter-210100645</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-first-quarter-210100645</guid>
<pubDate>Thu, 11 Dec 2025 21:01:00 GMT</pubDate>
<description>NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025. “We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trapp</description>
</item>
<item>
<title>Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-fourth-quarter-202400705</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-fourth-quarter-202400705</guid>
<pubDate>Wed, 29 Oct 2025 20:24:00 GMT</pubDate>
<description>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks On August 4, 2025, Joshua Fine was elected as the Company’s Chief Operating Officer NEWARK, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-W</description>
</item>
<item>
<title>Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-mourns-passing-lead-200100968</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-mourns-passing-lead-200100968</guid>
<pubDate>Tue, 28 Oct 2025 20:01:00 GMT</pubDate>
<description>NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as L</description>
</item>
<item>
<title>Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-announces-presentation-preliminary-120000168</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-announces-presentation-preliminary-120000168</guid>
<pubDate>Tue, 16 Sep 2025 12:00:00 GMT</pubDate>
<description>First data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients1 showed stabilization or improvement in CGI-S score Data presented at the15th International Congress of Inborn Errors of Metabolism (ICIEM) NEWARK, N.J., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that data from Cyclo Therapeutics’ Phase 3 TransportNPC™ ope</description>
</item>
<item>
<title>Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-announces-abstracts-accepted-120000723</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-announces-abstracts-accepted-120000723</guid>
<pubDate>Wed, 27 Aug 2025 12:00:00 GMT</pubDate>
<description>NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 at the upcoming 15th International Congress of Inborn Errors of Metabolism (ICIEM) being held September 2-6, 2025 in Kyoto, Japan. Details for the presentations are as follows: Session: Oral Prese</description>
</item>
<item>
<title>Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-announces-continuation-phase-110000048</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-announces-continuation-phase-110000048</guid>
<pubDate>Wed, 18 Jun 2025 11:00:00 GMT</pubDate>
<description>Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin), indicates that it is well-tolerated and has a safety profile consistent with the previously completed phase 1 and 2 studies and ongoing phase 1 open-label extension study NEWARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American</description>
</item>
<item>
<title>Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-third-quarter-110000885</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-third-quarter-110000885</guid>
<pubDate>Wed, 11 Jun 2025 11:00:00 GMT</pubDate>
<description>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected later this monthNEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025. “We are pleased</description>
</item>
<item>
<title>Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-inc-announces-final-200100727</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-inc-announces-final-200100727</guid>
<pubDate>Wed, 04 Jun 2025 20:01:00 GMT</pubDate>
<description>NEWARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today the final results and closing of its $25.0 million rights offering (the “Rights Offering”). The subscription period of the Rights Offering expired at 5:00 P.M. Eastern Time, on May 29, 2025. The Rights Offering resulted in subscriptions for 3,130,480 shares of Class B common stock at an exercise price of $1.28 per share for aggregate gross proceeds of $4,007,014.40.The subscri</description>
</item>
<item>
<title>Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-inc-provides-description-200100342</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-inc-provides-description-200100342</guid>
<pubDate>Tue, 20 May 2025 20:01:00 GMT</pubDate>
<description>NEWARK, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today provided an update to the subscription rights related to its Public Warrants in connection with its previously announced rights offering. Under the rights offering, Rafael Holdings has distributed one (1) non-transferable subscription right for each share of Class B common stock or Class A common stock, or for each share of Class B common stock issuable upon exercise of the outstanding w</description>
</item>
<item>
<title>Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-inc-announces-revised-110000848</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-inc-announces-revised-110000848</guid>
<pubDate>Mon, 05 May 2025 11:00:00 GMT</pubDate>
<description>NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as of May 9, 2025 (the “Record Date”) will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025. Former holders of Cyclo Therapeutics, Inc. who did</description>
</item>
<item>
<title>Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-inc-announces-proposed-203000779</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-inc-announces-proposed-203000779</guid>
<pubDate>Tue, 29 Apr 2025 20:30:00 GMT</pubDate>
<description>NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants (“Holders”) the opportunity to purchase additional shares of Rafael Holdings’ Class B common stock, par value $0.01 per share (“Class B Common Stock”), subject to the terms outlined below for an aggregate offering of $25 millio</description>
</item>
<item>
<title>Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-strengthens-focus-development-201500212</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-strengthens-focus-development-201500212</guid>
<pubDate>Thu, 24 Apr 2025 20:15:00 GMT</pubDate>
<description>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced that, following the merger with Cyclo Therapeutics, Bill Conkling will be stepping down as CEO and assuming an advis</description>
</item>
<item>
<title>Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-completes-merger-cyclo-105000124</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-completes-merger-cyclo-105000124</guid>
<pubDate>Wed, 26 Mar 2025 10:50:00 GMT</pubDate>
<description>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by sharehold</description>
</item>
<item>
<title>Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-second-quarter-215000846</link>
<guid isPermaLink="true">https://6ix.com/company/rafael-holdings-inc/news/rafael-holdings-reports-second-quarter-215000846</guid>
<pubDate>Thu, 13 Mar 2025 21:50:00 GMT</pubDate>
<description>The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals Post-merger the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025. “We look forward to the upcoming shareholder vote on our pending merger with Cyclo Th</description>
</item>
</channel>
</rss>